Načítá se...
Assessing Cancer Signal during Oral Antiplatelet Therapy in the Food and Drug Administration Adverse Event Reporting System: Mission Impossible
Whether aggressive prolonged dual antiplatelet therapy (DAPT) promotes solid cancer risks remains a critical unsolved issue. Since the evidence from randomized trials, affiliated U.S. Food and Drug Administration (FDA) reviews, meta-analyses, and national registries is mixed, the search is ongoing....
Uloženo v:
| Vydáno v: | TH Open |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Georg Thieme Verlag KG
2018
|
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6524855/ https://ncbi.nlm.nih.gov/pubmed/31249926 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1055/s-0037-1615253 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|